TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
Brief Summary: The purpose of this study is to determine if treatment with paclitaxel plus AMG 386 is superior to paclitaxel plus placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.

AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to grow.


Options:
A: Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Research Arm; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: PLD, Biological: Bevacizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Research Arm | Intervention Type: DRUG; Name: PLD; Assigned to Arm(s): Research Arm | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Research Arm
B: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: topotecan; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab
C: Arm Label: Cyclophosphamide and BIBF-1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Arm Label: Cyclophosphamide and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIBF 1120 | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): Cyclophosphamide and BIBF-1120, Cyclophosphamide and placebo
D: Arm Label: AMG 386; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: AMG 386 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: AMG 386 Placebo, Drug: Paclitaxel | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): AMG 386 Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386 Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck (VIMS) - Shoulder Function
Brief Summary: Basic strength training for the neck/shoulder muscles can decrease intensity of neck/shoulder pain, but it is uncertain whether training should focus directly on the upper trapezius - which is most often tender - or on the lower compartments and serratus anterior.

We hypothesize that strengthening exercise for the lower and middle trapezius as well as the serratus anterior will decrease intensity of neck/shoulder pain among office workers


Options:
A: Arm Label: Cognitive and physical program; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive, Relaxation, Exercise Therapy | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive, Relaxation, Exercise Therapy; Assigned to Arm(s): Cognitive and physical program
B: Arm Label: Training; Type: EXPERIMENTAL; Interventions: Behavioral: Training | Arm Label: Reference; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reference | Intervention Type: BEHAVIORAL; Name: Training; Assigned to Arm(s): Training | Intervention Type: BEHAVIORAL; Name: Reference; Assigned to Arm(s): Reference
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: spinal manipulation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: Spinal manipulation + exercises | Intervention Type: OTHER; Name: spinal manipulation; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Spinal manipulation + exercises; Assigned to Arm(s): 3
D: Arm Label: Pain Management + Training; Type: ACTIVE_COMPARATOR; Interventions: Other: Education and training | Arm Label: Pain Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Pain management | Intervention Type: OTHER; Name: Education and training; Assigned to Arm(s): Pain Management + Training | Intervention Type: BEHAVIORAL; Name: Pain management; Assigned to Arm(s): Pain Management

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of an Internet-based Guided Self-help Training for Chronic Tinnitus: A Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine the efficacy of a cognitive behavioral guided self-help training provided via the internet on tinnitus distress in a German sample.


Options:
A: Arm Label: experimental group; Type: EXPERIMENTAL; Interventions: Behavioral: CBT-based internet-intervention for tinnitus | Arm Label: weekly check-in group with delayed treatment; Type: OTHER; Interventions: Behavioral: CBT-based internet-intervention for tinnitus | Intervention Type: BEHAVIORAL; Name: CBT-based internet-intervention for tinnitus; Assigned to Arm(s): experimental group, weekly check-in group with delayed treatment
B: Arm Label: TRT / EMDR; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: TRT / CBT | Arm Label: TRT / CBT; Type: ACTIVE_COMPARATOR; Interventions: Other: TRT / EMDR | Intervention Type: OTHER; Name: TRT / EMDR; Assigned to Arm(s): TRT / CBT | Intervention Type: BEHAVIORAL; Name: TRT / CBT; Assigned to Arm(s): TRT / EMDR
C: Arm Label: Internet-based self-help; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based guided self-help for tinnitus | Arm Label: Discussion forum group; Type: ACTIVE_COMPARATOR; Interventions: Other: Internet discussion forum | Intervention Type: BEHAVIORAL; Name: Internet-based guided self-help for tinnitus; Assigned to Arm(s): Internet-based self-help | Intervention Type: OTHER; Name: Internet discussion forum; Assigned to Arm(s): Discussion forum group
D: Intervention Type: BEHAVIORAL; Name: Biofeedback-based cognitive-behavioural intervention; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Trial to Evaluate the Effect of East-West Collaborative Medicine on Chronic Cervical Pain: a Pilot Study
Brief Summary: The purpose of this study is to assess the effect of East-West collaborative medicine on chronic cervical pain.


Options:
A: Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Usual care | Arm Label: Integrative care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Integrative care | Intervention Type: PROCEDURE; Name: Integrative care; Assigned to Arm(s): Integrative care | Intervention Type: PROCEDURE; Name: Usual care; Assigned to Arm(s): Usual care
B: Arm Label: medication(Zaltoprofen); Type: ACTIVE_COMPARATOR; Interventions: Procedure: acupuncture | Arm Label: Acupuncture; Type: ACTIVE_COMPARATOR; Interventions: Procedure: acupuncture | Arm Label: Zalprofen plus Acupuncture; Type: ACTIVE_COMPARATOR; Interventions: Procedure: acupuncture | Intervention Type: PROCEDURE; Name: acupuncture; Assigned to Arm(s): Acupuncture, Zalprofen plus Acupuncture, medication(Zaltoprofen)
C: Arm Label: traditional acupuncture (tACP); Type: EXPERIMENTAL; Interventions: Device: Acupuncture | Arm Label: sham acupuncture (sACP); Type: PLACEBO_COMPARATOR; Interventions: Device: Sham acupuncture | Intervention Type: DEVICE; Name: Acupuncture; Assigned to Arm(s): traditional acupuncture (tACP) | Intervention Type: DEVICE; Name: Sham acupuncture; Assigned to Arm(s): sham acupuncture (sACP)
D: Arm Label: Standard ED management alone; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard ED management alone | Arm Label: Acupuncture plus standard ED management; Type: EXPERIMENTAL; Interventions: Procedure: Acupuncture plus standard ED management | Intervention Type: PROCEDURE; Name: Acupuncture plus standard ED management; Assigned to Arm(s): Acupuncture plus standard ED management | Intervention Type: PROCEDURE; Name: Standard ED management alone; Assigned to Arm(s): Standard ED management alone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Tailored Dose of Varenicline on Post-quitting Urges to Smoke
Brief Summary: Varenicline is a partial nicotinic agonist which acts on alpha4 beta2 nicotinic receptors. It is presumed to alleviate withdrawal discomfort, but also to diminish rewarding effects of cigarettes. The standard varenicline dosing has been formulated to avoid adverse reactions (primarily nausea) in sensitive clients. The downside of this cautious approach is that a substantial proportion of clients may be under-dosed. A blanket dose increase would inevitably increase the incidence of side effects, but it is likely that tailoring varenicline dosing to clients' needs would be safe and may further increase varenicline's efficacy.

This study will recruit 200 smokers who report little change to their enjoyment of cigarettes and no nausea, during the first week of varenicline use. These smokers will be randomised to receive the standard dose plus placebo or plus individualised varenicline dose up to 5mg, titrated over the next week prior to their target quit day. Urges to smoke, and other withdrawal symptoms, experienced during the study period will be compared between groups to see if the tailored therapy may be useful.


Options:
A: Arm Label: Varenicline + Active Tailored Dose; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline + Placebo Tailored Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Tailored Dose | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose, Varenicline + Placebo Tailored Dose
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Chantix (varenicline); Type: EXPERIMENTAL; Interventions: Drug: Chantix | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix (varenicline) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Tailored Dose of Varenicline on Post-quitting Urges to Smoke
Brief Summary: Varenicline is a partial nicotinic agonist which acts on alpha4 beta2 nicotinic receptors. It is presumed to alleviate withdrawal discomfort, but also to diminish rewarding effects of cigarettes. The standard varenicline dosing has been formulated to avoid adverse reactions (primarily nausea) in sensitive clients. The downside of this cautious approach is that a substantial proportion of clients may be under-dosed. A blanket dose increase would inevitably increase the incidence of side effects, but it is likely that tailoring varenicline dosing to clients' needs would be safe and may further increase varenicline's efficacy.

This study will recruit 200 smokers who report little change to their enjoyment of cigarettes and no nausea, during the first week of varenicline use. These smokers will be randomised to receive the standard dose plus placebo or plus individualised varenicline dose up to 5mg, titrated over the next week prior to their target quit day. Urges to smoke, and other withdrawal symptoms, experienced during the study period will be compared between groups to see if the tailored therapy may be useful.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline
B: Arm Label: Varenicline + Active Tailored Dose; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline + Placebo Tailored Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Tailored Dose | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose, Varenicline + Placebo Tailored Dose
C: Arm Label: Placeo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: St. John's Wort-900 mg/day; Type: EXPERIMENTAL; Interventions: Drug: St. John's Wort-900 mg/day | Arm Label: St. John's Wort-1800 mg/day; Type: EXPERIMENTAL; Interventions: Drug: St. John's Wort-1800mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placeo | Intervention Type: DRUG; Name: St. John's Wort-900 mg/day; Assigned to Arm(s): St. John's Wort-900 mg/day | Intervention Type: DRUG; Name: St. John's Wort-1800mg/day; Assigned to Arm(s): St. John's Wort-1800 mg/day
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine Patch; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicotine Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Transdermal Nicotine Patch; Assigned to Arm(s): Transdermal Nicotine Patch

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Tailored Dose of Varenicline on Post-quitting Urges to Smoke
Brief Summary: Varenicline is a partial nicotinic agonist which acts on alpha4 beta2 nicotinic receptors. It is presumed to alleviate withdrawal discomfort, but also to diminish rewarding effects of cigarettes. The standard varenicline dosing has been formulated to avoid adverse reactions (primarily nausea) in sensitive clients. The downside of this cautious approach is that a substantial proportion of clients may be under-dosed. A blanket dose increase would inevitably increase the incidence of side effects, but it is likely that tailoring varenicline dosing to clients' needs would be safe and may further increase varenicline's efficacy.

This study will recruit 200 smokers who report little change to their enjoyment of cigarettes and no nausea, during the first week of varenicline use. These smokers will be randomised to receive the standard dose plus placebo or plus individualised varenicline dose up to 5mg, titrated over the next week prior to their target quit day. Urges to smoke, and other withdrawal symptoms, experienced during the study period will be compared between groups to see if the tailored therapy may be useful.


Options:
A: Arm Label: Varenicline + Active Tailored Dose; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline + Placebo Tailored Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Tailored Dose | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose, Varenicline + Placebo Tailored Dose
B: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline
D: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm III; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Tailored Dose of Varenicline on Post-quitting Urges to Smoke
Brief Summary: Varenicline is a partial nicotinic agonist which acts on alpha4 beta2 nicotinic receptors. It is presumed to alleviate withdrawal discomfort, but also to diminish rewarding effects of cigarettes. The standard varenicline dosing has been formulated to avoid adverse reactions (primarily nausea) in sensitive clients. The downside of this cautious approach is that a substantial proportion of clients may be under-dosed. A blanket dose increase would inevitably increase the incidence of side effects, but it is likely that tailoring varenicline dosing to clients' needs would be safe and may further increase varenicline's efficacy.

This study will recruit 200 smokers who report little change to their enjoyment of cigarettes and no nausea, during the first week of varenicline use. These smokers will be randomised to receive the standard dose plus placebo or plus individualised varenicline dose up to 5mg, titrated over the next week prior to their target quit day. Urges to smoke, and other withdrawal symptoms, experienced during the study period will be compared between groups to see if the tailored therapy may be useful.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Varenicline + Active Tailored Dose; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline + Placebo Tailored Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Tailored Dose | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose, Varenicline + Placebo Tailored Dose
D: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Tailored Dose of Varenicline on Post-quitting Urges to Smoke
Brief Summary: Varenicline is a partial nicotinic agonist which acts on alpha4 beta2 nicotinic receptors. It is presumed to alleviate withdrawal discomfort, but also to diminish rewarding effects of cigarettes. The standard varenicline dosing has been formulated to avoid adverse reactions (primarily nausea) in sensitive clients. The downside of this cautious approach is that a substantial proportion of clients may be under-dosed. A blanket dose increase would inevitably increase the incidence of side effects, but it is likely that tailoring varenicline dosing to clients' needs would be safe and may further increase varenicline's efficacy.

This study will recruit 200 smokers who report little change to their enjoyment of cigarettes and no nausea, during the first week of varenicline use. These smokers will be randomised to receive the standard dose plus placebo or plus individualised varenicline dose up to 5mg, titrated over the next week prior to their target quit day. Urges to smoke, and other withdrawal symptoms, experienced during the study period will be compared between groups to see if the tailored therapy may be useful.


Options:
A: Arm Label: Varenicline + Active Tailored Dose; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline + Placebo Tailored Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Tailored Dose | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose, Varenicline + Placebo Tailored Dose
B: Arm Label: Varenicline treatment as usual (TAU); Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline directly observed therapy; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline directly observed therapy, Varenicline treatment as usual (TAU)
C: Arm Label: Arm I (varenicline); Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II (nicotine patch); Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I (varenicline) | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): Arm II (nicotine patch)
D: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A

Answer: A